MEDIOCON INC – Ixabepilone is a semisynthetic epothilone-class antineoplastic agent that acts as a microtubule-stabilizing compound. It was developed as an anticancer drug for the treatment of certain advanced or metastatic breast cancers, particularly in patients whose tumors had progressed following prior chemotherapy.
Ixabepilone is a semisynthetic analog of epothilone B. It binds to tubulin and promotes microtubule stabilization, thereby interfering with the normal dynamic reorganization of microtubules required for cell division.
Ixabepilone is particularly relevant to oncology pharmaceutical development because of its activity against cancer cells and its ability to retain activity in certain models involving resistance to taxane-based chemotherapy.
Product Name: Ixabepilone
CAS Number: 219989-84-1
Molecular Formula: C₂₇H₄₂N₂O₅S
Molecular Weight: 506.70 g/mol
Chemical Class: Epothilone Analog
Therapeutic Class: Antineoplastic Agent / Microtubule Stabilizer
IUPAC Name: (1S,3S,6R,7R,10S,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-methyl-2-(2-methylthiazol-4-yl)ethenyl]-5-oxa-4-azabicyclo[10.3.1]hexadecane-6,12-dione
Development Code: BMS-247550
Synonyms: Ixabepilone, Ixabepilona
Ixabepilone is a microtubule-stabilizing agent. It binds to tubulin and promotes the formation and stabilization of microtubules.
This interferes with the normal dynamic processes required for mitotic cell division, resulting in cell-cycle arrest and subsequent cancer-cell death.
MEDIOCON INC focuses on supplying pharmaceutical and specialty chemical ingredients with emphasis on quality, consistency, technical documentation and reliable supply.
Ixabepilone quality evaluation may include:
The exact acceptance criteria should be confirmed against the current approved specification and batch-specific Certificate of Analysis.
Ixabepilone is associated with:
The U.S. FDA-approved product Ixempra (ixabepilone) was indicated for certain patients with metastatic or locally advanced breast cancer after failure of specified prior chemotherapy regimens.
Ixabepilone is generally described as a white to off-white solid/powder.
Appearance: White to off-white powder/solid
The exact commercial appearance specification should be confirmed against the applicable MEDIOCON INC specification and batch COA.
Product availability, packaging configuration, Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS), technical specifications and analytical documentation should be confirmed with MEDIOCON INC according to the intended pharmaceutical application.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white powder/solid |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Ixabepilone API Manufacturer and Supplier in India (CAS 219989-84-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Ixabepilone API Manufacturer and Supplier in India is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance